CODXCo-Diagnostics, Inc.
The schedule
- Thu15Oct
If operating losses remain steep and cash continues to fall through 2026, Co-Diagnostics may pursue an equity raise or similar financing around late 2026; a well-structured deal aligned with a concrete commercial plan could stabilize the stock near $1.3, but a deeply discounted or poorly messaged offering would likely pressure shares toward $1.30.
- Mon15Feb
Into early 2027, Co-Diagnostics may pursue additional FDA 510(k), CE Mark, or similar clearances and distribution deals for its next-generation molecular diagnostics; a meaningful regulatory win or partnership that broadens market access could support a recovery toward $0.95, while setbacks, non-approvals, or tepid demand would likely keep pressure on the stock toward $0.95.
- Thu13May
Q3 2026 results and early commentary on 2027 will be a key checkpoint on whether Co-Diagnostics is transitioning from a legacy COVID testing story to a sustainable infectious disease diagnostics platform; confirmation of stabilizing revenues and a cleaner cost structure could lift shares toward $1.10, while ongoing revenue stagnation or a soft outlook would likely leave the stock closer to $0.6.
- Thu12Aug
Past
- Thu13Aug
Q2 2026 earnings will test whether any mid-year product initiatives are translating into sustained revenue recovery; evidence of sequential growth with controlled cash burn could support a move toward $2.30, while another quarter of minimal sales would likely send shares down toward $2.30 as investors price in a higher probability of future dilution.
- Wed22Jul
Actual outcome: Bear · $1.21 at outcome
Co-Diagnostics announced the initiation of clinical studies for a Tuberculosis test in India and the provision of Ebola test kits for analytical studies, but failed to provide definitive commercial traction or point-of-care launch updates. The absence of near-term revenue drivers and clear timelines for broader adoption disappointed investors, leading to a 37.7% decline in the stock price.
Around mid-2026, Co-Diagnostics is likely to update investors on its next-generation molecular diagnostics menu and potential point-of-care or CLIA-waived offerings; clear timelines and evidence of commercial traction could re-rate the stock toward $1.70, while further delays or minimal adoption would reinforce concerns and keep shares closer to $0.7.
- Thu14May
Actual outcome: Bull · $3.84 at outcome
Co-Diagnostics reported Q1 earnings that were exactly in-line with estimates, alongside updates on its clinical strategy and international expansion. The stock's massive surge well past the bull target was driven by subsequent news that the company is developing an Ebola assay strategy in response to a global outbreak alert, coupled with a $3.0 million private placement that helped alleviate cash runway concerns.
Q1 2026 results should clarify whether Co-Diagnostics can stabilize revenue after the collapse in COVID-related testing and how long the company can fund operations given a trailing free cash outflow of about $6.3M against $11.9M of cash; a cleaner cost base or better-than-expected assay sales could support a move toward $2.20, while continued tiny revenue prints and heavy losses would likely push shares toward $2.20.
